Slide 1: Exchange filing cover letter: Investor Presentation
4th November, 2022 (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor, Dalal Street Plot no. C/1, G Block, Mumbai 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA (3) SOCIETE DE
Slide 2: Investor Presentation Q2FY23
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q2FY23 4-11-2022
Slide 3: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o
Slide 4: Q2FY23 Performance Key Highlights
Q2FY23 Performance Strong CLICK TO One-India EDIT MASTER momentum TITLE STYLE and US differentiated portfolio unlocking drives revenue and profitability KEY HIGHLIGHTS Overall Revenue EBITDA Margin R&D Investment2 INR 5,829 Cr Overall INR 335 Cr 22.3% 6% 12% Adj. margin1 ~24% 22% 5.8% overall Ex-cov
Slide 5: Continued traction on transforming into a digitally native organization
CLICK TO EDIT MASTER TITLE STYLE Continued traction on transforming into a digitally native organization • Amongst the first pharmaceutical companies in India and Asia to be recognized for adopting 4IR technologies to digitally transform operations • Demonstrates advanced technologies to drive produ
Slide 6: Financial Performance – Q2FY23
Financial Performance – Q2FY23 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,829 Cr 6% YoY EBITDA2 INR 1,302 Cr │ 22.3% 6% YoY Revenue1 Break-up Q2 FY23 (Consolidated) API, 3% Actuals Others, 1% vs Q2 FY 22 (INR Cr) International Markets, Total Revenue from 13% 5,829 6% Operations India, 44% EBITD
Slide 7: Continued focus on building balance sheet strength
Continued focus on building balance sheet strength CLICK TO EDIT MASTER TITLE STYLE Total Debt1 Cash Balances2 Net Cash3 (INR Cr) (INR Cr) (INR Cr) 5,211 5,060 4,965 3,909 4,127 3,992 1,084 1,056 1,068 Mar'22 Jun'22 Sept'22 Mar'22 Jun'22 Sept'22 Mar'22 Jun'22 Sept'22 1. Total debt includes lease lia
Slide 8: Prescription: Driving wellness ecosystem
Driving wellness ecosystem with focus on New Science, Better Reach and Digital- first approach CLICK TO EDIT MASTER TITLE STYLE New Science Better Reach Digital first Synchrobreathe offerings Affordable & Early Diagnosis Digital initiatives SABA (Levolin®) | LAMA (Tiova®) Prescription Expand to 1 la
Slide 9: One India: Robust core portfolio traction across therapies and business segments
One India (Rx + Gx+ CHL1): Robust core portfolio traction across therapies and CLICK business TO EDIT MASTER TITLE STYLE segments 41% 6th consecutive quarter of One-India Rx 38% 29% market beating growth in core 16% branded prescription business 16% 15% 9% (ex-covid) INR Cr. 16% Q2 Y-o-Y 12% 10% 0%
Slide 10: Global consumer wellness franchise improving health outcomes
Global consumer wellness franchise improving health outcomes CLICK TO EDIT MASTER TITLE STYLE One-India Flagship Brands 675+ INR Cr ↑ 26% ↑ 35% ↑ 34% ↑ 8% H1FY23 revenue ~9% ↑ 26% ↑ 15% ↑ 8% ↑ 32% Contribution of Global South Africa Consumer franchise to overall revenues in Flagship Brands H1FY23 65
Slide 11: North America: Contribution of differentiated products continues to expand
North America: The contribution of differentiated products continues CLICK TO EDIT MASTER TITLE STYLE to expand North America Revenue ($m) Average Quarterly 179 run rate 15% 160 155 150 143 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Budesonide Albuterol Lanreotide Respiratory, Peptide injectables & Arfomote
Slide 12: North America: Unlocking of differentiated portfolio
North America: Unlocking of differentiated portfolio CLICK TO EDIT MASTER TITLE STYLE North America Growth driven by successful launch of Lenalidomide and continued market share expansion in Lanreotide 505b2 $ Mn Q2 Y-o-Y 179 25% Q4FY22 Q1FY23 Q2FY23 Sustained market share1 1.9% 4.6% 9.6% ramp-up in
Slide 13: ANDA & NDA Portfolio & Pipeline (As on 30th September 2022)
ANDA1 & NDA Portfolio & Pipeline (As on 30th September 2022) CLICK TO EDIT MASTER TITLE STYLE 14 61 9 5 18 80 3 8 1 41 7 8 Approved Tentatively Under Approval ANDAs/NDAs Approved ANDAs ANDAs/NDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs/NDAs 164 19 72 255 Approved Tentatively Under Approval Total
Slide 14: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access CLICK TO EDIT MASTER TITLE STYLE $ Mn Q2 Y-o-Y | QoQ South Africa2 38 22 28 34 20 13 74 ❖ SA private market recovery on track; 28% sequential growth in 6 53 62 ZAR terms ❖ In secondary terms, strong demand continues with overall Q2FY22
Slide 15: International Markets and API
International Markets and API CLICK TO EDIT MASTER TITLE STYLE International Markets API $ Mn Q2 Y-o-Y $ Mn Q2 Y-o-Y 111 -14% 96 23 -18% 19 Q2FY22 Q2FY23 Q2FY22 Q2FY23 Key Business Highlights Key Business Highlights ❖ Maintained scale over Q2FY22 excluding ❖ Continued growth in emerging markets covi
Slide 16: Continued progress on FY23 strategic priorities
Continued progress on FY23 strategic priorities CLICK TO EDIT MASTER TITLE STYLE Accelerate growth Building big prescription brands across Driving penetration and Consumer insighting driving portfolio in One-India chronic therapies, improved accessibility of brands for unmet expansion to address wel
Slide 17: Profit and Loss statement summary
Profit and Loss statement summary CLICK TO EDIT MASTER TITLE STYLE Q2 FY23 Q1 FY23 Q2 FY22 Particulars (INR Crores) (INR Crores) (INR Crores) Revenue from sale of products 5,759.3 5,317.9 5,485.8 Other operating income 69.3 57.3 34.0 Income from operations 5,828.5 5,375.2 5,519.8 Material cost 2,160
Slide 18: Balance sheet summary
Balance sheet summary CLICK TO EDIT MASTER TITLE STYLE Sep-22 Jun-22 Mar-22 Sep-22 Jun-22 Mar-22 Particulars Particulars (INR Crores) (INR Crores) (INR Crores) (INR Crores) (INR Crores) (INR Crores) Property, plant and equipment 5,080.0 5,059.0 5,164.4 Share capital 161.4 161.4 161.4 Capital work-in
Slide 19: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com Ankit Bhembre Investor.Relations@cipla.com For more information please visit www.cipla.com